Getinge lags profit estimates as uncertainty curbs investments in medical equipment

Getinge’s adjusted EBITA fell 18% to 824 million Swedish crowns in Q1, missing consensus of 829 million, as ventilator sales declined and lower investment spending hurt orders in project-based equipment. Currency headwinds reduced core profit by 122 million crowns and tariff costs by 104 million, while the company said geopolitical uncertainty is weighing on pharma investment. Getinge reaffirmed its 2026 forecast for 3% to 5% organic sales growth.

Analysis

The key second-order read is that Getinge is not just facing a cyclical pause in capital spending; it is exposed to a broader risk-off in hospital/pharma capex where projects can be delayed without being canceled, creating a lagged revenue headwind that can persist for multiple quarters. That matters because project-heavy medtech names typically see orders hold up first and margins compress later, so the current setup is more about a near-term earnings de-rating than a demand collapse. If geopolitical uncertainty stays elevated, the weakest segment is likely the high-ticket equipment basket, while consumables and service should remain comparatively defensive.

Tariffs and FX are also doing more than shaving reported EBITA: they are widening the gap between headline price increases and realized margin recovery. In a market where U.S. exposure is material, the combination of delayed pass-through, dollar volatility, and supply-chain reconfiguration tends to pressure working capital and free cash flow before it shows up in revenue. Competitively, larger global peers with more localized manufacturing and broader service mix should be able to defend share better, while smaller import-reliant suppliers may either lose bids or have to undercut pricing to stay relevant.

The market may be underestimating the asymmetry in timing: negative revision risk is front-loaded over the next 1-2 quarters, but any improvement in U.S.-China tariff rhetoric or a stabilization in healthcare/pharma capital budgets could spark a sharp rebound because order growth is still positive. The contrarian point is that resilient order intake suggests this is not a demand vacuum, but a deferral cycle — which argues against extrapolating the earnings miss into a multi-year volume problem. That makes the stock more of a tactical short/hedge candidate than a structural broken story, unless management starts signaling that pricing is no longer covering tariff leakage.

Key Decisions for Investors

• Short Getinge on a 1-2 quarter horizon via the local listing or ADR proxy if available; thesis is earnings downside from margin compression and delayed tariff pass-through, with upside limited until pricing fully catches up.
• Pair trade: long larger diversified medtech names with stronger service/consumables mix against Getinge-style capex-exposed equipment makers; this isolates the project-delay risk and should outperform if hospital budgets stay cautious over the next 3-6 months.
• If you need a hedge for healthcare capex softness, buy short-dated put spreads on European medtech cyclicals into the next earnings season; risk/reward is favorable because estimate revisions usually lag the first margin miss.
• Avoid chasing the order-growth headline; wait for either a second consecutive quarter of margin stabilization or a clear improvement in tariff pass-through before adding long exposure, which likely takes 2+ quarters.